Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study

09:00 EDT 8 Sep 2013 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced results from a Phase 2a viral challenge study of TCN-032 for the universal treatment of influenza A. The results of this study ...

Other Sources for this Article

MacDougall Biomedical Communications
Doug MacDougall or Michelle Avery, 781-235-3060

NEXT ARTICLE

More From BioPortfolio on "Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Immunology
Latest News Clinical Trials Research Drugs Reports Corporate
Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand and prevent autoimmune condtions, cancers of immune cells and immune deficiencies. Immunotherapy i...

Advertisement